Market Overview

Raymond James: Flexion Therapeutics Estimates Are A Stretch

Raymond James: Flexion Therapeutics Estimates Are A Stretch

Flexion Therapeutics Inc (NASDAQ: FLXN) is scheduled to report preliminary fourth-quarter Zilretta sales results and initial 2019 guidance. This will nudge expectations toward reality, as the current consensus estimates for Zilretta sales appear too aggressive, according to Raymond James.

The Analyst

Analyst Elliot Wilbur maintains a Strong Buy rating on Flexion Therapeutics.

The Thesis

Zilretta is a “highly differentiated asset,” and its efficacy and safety profile is compelling, which supports a peak sales potential close to $700 million by 2030, Wilbur said in a Wednesday note. 

Flexion is likely to meet the 2018 consensus sales estimates of $23 million, with $10 million being generated in Q4, given Zilretta’s early launch, the analyst said. Yet the Street estimate for 2019 Zilretta sales of $98 million seems like a “stretch target,” while the 2020 consensus of $229 million appears “ridiculously out of touch with reality,” Wilbur said. 

The expected estimate reductions should not be considered a negative given Flexion’s current share price levels and highly favorable reward-risk scenario, the analyst said. The reductions in estimates may keep buyers on the sidelines and short sellers engaged “until the adjustment is fully completed,” he said. 

Price Action

Flexion Therapeutics shares were down 0.8 percent at $12.36 at the time of publication Thursday.

Related Links:

The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen

Flexion Therapeutics Just Hit A Major Milestone

Latest Ratings for FLXN

Dec 2019Initiates Coverage OnBuy
Nov 2019Initiates Coverage OnBuy
May 2019UpgradesHoldBuy

View More Analyst Ratings for FLXN
View the Latest Analyst Ratings

Posted-In: Elliot Wilbur Raymond JamesAnalyst Color Reiteration Analyst Ratings Best of Benzinga


Related Articles (FLXN)

View Comments and Join the Discussion!

Latest Ratings

PLCEB. Riley FBRDowngrades59.0
ASPUCanaccord GenuityMaintains11.0
AAPLEvercore ISI GroupMaintains305.0
THTXMackie ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Mid-Day Market Update: Apple Falls On Lowered Sales Guidance; Kitov Pharma Shares Jum

Today's Pickup: New Chinese e-Commerce Law Prohibits Copyright Violations And Illegal Knockoffs